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Abstract
Background: Recent studies suggest that rotenone alters cell signal transduction pathways in a
manner similar to glucocorticoids. Histological and biochemical markers of glucocorticoid effects
in vivo, evaluated in our laboratories, provide further evidence for similarities in the activity of
glucocorticoids and rotenone. The purpose of this study was to investigate the mechanism by
which rotenone produces glucocorticoid-like effects.
Methods: Male B6C3F1 mice were treated for 7 days with rotenone (600 ppm in diet), the
glucocorticoid antagonist RU486 (2 mg/kg/day, ip), corticosterone (2 mg/kg/day, ip), or both
rotenone and RU 486. Control mice received drug-free diet and the vehicle (corn oil, ip). Following
preservation in 10% neutral buffered formalin, tissues were embedded in paraffin. Sections were
stained with hematoxylin, eosin, and were examined by light microscopy. Tissue sections were
processed for in situ enzymatic end labeling of 3'-hydroxy-DNA strand breaks, a measure of
apoptosis. Corticosterone was quantified in sera, using a solid phase radioimmunoassay kit. Cells
(cell line 1470.2 derived from C127 mouse mammary adenocarcinoma cells) were transiently
transfected with 5 µg of pLTRLuc and 1 µg of β-Galactosidase expression vectors using a BTX
square-wave pulser at 155 V, 4 pulses (40 ms each). Cells were then treated with dexamethasone,
rotenone, or a mixture of both for 6 hr, harvested and assayed for luciferase and β-Galactosidase
activity. Using Root Mean Square (RMS) fit analysis (Alchemy™, Tripose, Inc., St Louis, MO), we
assessed possible structural similarities between rotenone and corticosterone,
dehydrocorticosterone, glucocorticoid antagonists ZK 98.299, and RU 486. RMS fit was calculated
by selecting three atoms in each of the molecules, followed by calculating the distance between
these atoms. An RMS value of zero between two molecules indicates identical molecular
characteristics. A positive value suggests diminished similarity with a value of 1 or higher excluding
any such similarities.
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Results: Although the stimulatory effect exerted by rotenone on hepatocellular apoptosis was in
the opposite direction of that produced by the glucocorticoid antagonist RU 486, data suggested
that rotenone does not directly activate the glucocorticoid receptor. Molecular fitting of rotenone
to glucocorticoid receptor agonists and antagonists as well as examination of the transcriptional
activation of a glucocorticoid-responsive reporter gene (Mouse MammaryTumorVirus) in response
to rotenone indicated that it is highly unlikely that rotenone interacts directly with the
glucocorticoid receptor. However, feeding male B6C3F1 mice a diet containing rotenone (600 ppm
for 7 days) resulted in a 3-fold increase in serum levels of corticosterone relative to control animals.
Corticosterone is the major glucocorticoid in rodents.
Conclusion: Rotenone does not interact directly with the glucocorticoid receptor. Elevation of
serum corticosterone levels in response to rotenone may explain the glucocorticoid-like effects of
this compound, and may play a role in its anti-hepatocarcinogenic effect.
Background
Previously, we [1] demonstrated that rotenone, a pesticide
which specifically inhibits complex I of the mitochondrial
respiratory chain [2], altered hepatocellular signal trans-
duction pathways in a manner consistent with its anticar-
cinogenic activity in the liver [3]. Treatment of male
B6C3F1 mice with rotenone enhanced hepatic apoptosis,
inhibited cell proliferation and altered the expression of
oncogenes and tumor suppressor genes [1].
Since rotenone is structurally similar to steroids and since
the effects of rotenone and glucocorticoids appear similar
[4,5], we tested the hypothesis that rotenone may act as a
glucocorticoid receptor agonist. The impact of rotenone
on several glucocorticoid-responsive organs (thymus, ad-
renal gland and liver), was evaluated in male B6C3F1
mice, and was compared with effects produced by corti-
costerone as well as by the glucocorticoid antagonist RU
486. Furthermore, we used molecular fitting techniques to
examine the potential structural similarities between glu-
cocorticoids and rotenone, and tested the ability of roten-
one to activate the transcription of a glucocorticoid
receptor responsive reporter gene.
The results of our study demonstrate that despite the fact
that rotenone produces histological and biochemical ef-
fects similar to those produced by corticosterone, gluco-
corticoids and rotenone do not share structural molecular
similarities. Moreover the transcriptional activation pro-
file of glucocorticoids and rotenone were different. Taken
collectively, data suggest that rotenone does not directly
activate the glucocorticoid receptor. Interestingly, dietary
rotenone significantly increased serum corticosterone lev-
els in treated mice. This finding strongly suggests that glu-
cocorticoid-like-effects of rotenone may be a consequence
of increasing serum corticosterone levels caused as a result
of exposure to rotenone.
Methods
Animal Treatments
Male B6C3F1 mice (Charles River, Portage. Michigan)
weighing 20–25 g were maintained on a daily cycle of al-
ternating 12 hours periods of light and darkness. Mice
were randomly divided into five groups. In the first group,
mice received rotenone (600 ppm in diet). In the second
group, mice received glucocorticoid antagonist RU486 (2
mg/kg/day, ip), and in the third group, mice received cor-
ticosterone (2 mg/kg/day, ip). Another group of mice re-
ceived both rotenone and RU 486. Control mice received
drug-free diet and the vehicle (corn oil, ip). All animals
were treated for 7 days, at which time mice were anethe-
sized, and tissues were isolated, blotted and weighed im-
mediately. Care and handling of animals were in
accordance with the guidelines of the USDA and Animal
Welfare Act Guide for the Care and Use of Laboratory An-
imals, Department of Hea1th and Human Services Publi-
cation No 85–23.
Histological Studies
Following preservation in 10% neutral buffered formalin,
tissues were embedded in paraffin, and then sectioned (4
µm thickness). Sections were stained with hematoxylin,
eosin, and were examined by light microscopy. Magnifica-
tion of micrographs was 200×.
Hepatocellular Apoptosis
Tissue sections were processed for in situ enzymatic end la-
beling of 3'-hydroxy-DNA strand breaks, a measure of ap-
optosis, as previously described [1].
Transfections
Cell line 1470.2 derived from C127 mouse mammary ad-
enocarcinoma cells was used to determine whether roten-
one could affect glucocorticoid-induced transcription of
the Mouse Mammary Tumor Virus(MMTV) promoter [6].
Cells were maintained in Dulbecco's modified Eagle's me-
dium containing 10% charcoal-stripped fetal calf serum.
Subconfluent cells were transiently transfected with 5 µgJournal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/2
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of pLTRLuc and 1 µg of β-Galactosidase expression vectors
using a BTX square-wave pulser at 155 V, 4 pulses (40 ms
each). PLTRLuc consists of a full-length MMTV Long Ter-
minal Repeat (LTR) driving a luciferase reporter gene [6].
After 14 h transfection, cells were treated with indicated
concentrations of dexamethasone, rotenone, or a mixture
of both for 6 hr. Cells were harvested and assayed for luci-
ferase and β-Galactosidase activity as previously described
[6]. All transfections were done in triplicates and all exper-
iments were repeated at least four times.
Molecular Fitting
Using Root Mean Square (RMS) fit analysis (Alchemy™,
Tripose, Inc., St Louis, MO), we assessed possible structur-
al similarities between rotenone and corticosterone, dehy-
drocorticosterone, glucocorticoid antagonists ZK 98.299,
and RU 486. RMS fit was calculated by selecting three at-
oms in each of the molecules, followed by calculating the
distance between these atoms. An RMS value of zero be-
tween two molecules indicates identical molecular charac-
teristics. A positive value suggests diminished similarities
with a value of 1 or higher excluding any such similarities.
Quantification of Serum Corticosterone Levels
Corticosterone was quantified in sera, using a solid phase
radioimmunoassay kit (Diagnostic Products Corporation,
Los Angeles, CA). In this assay, 125I-labeled rat corticoster-
one was allowed to compete with corticosterone for anti-
body sites in the sample. Since corticosterone levels
follow diurnal variations, assays were done at the same
time periods for the different treatment groups.
Statistical Analysis
Means of various treatment groups were compared with
respective controls and were analyzed by ANOVA (Stat
Work™). Statistical significance was defined as p < 0.05.
All data reported are means ± SEM of 4–7 mice per group.
Results
Effect of Rotenone on Thymus and Adrenal Glands
Since the thymus and the adrenal gland are sensitive indi-
cators of changes in the animal glucocorticoid status, we
investigated the effect of rotenone on these two organs. In
control animals, thymus/body weight ratios were 0.26 ±
0.02 (Fig 1). Treatment of mice with exogenous corticos-
terone resulted in a significant decline of 42% in thymus/
body weight ratios down to 0.15 ± 0.03 (Fig 1). Rotenone
also decreased thymus/body weight ratios to 0.17 ± 0.02
(Fig 1), values that were similar to those observed in re-
sponse to corticosterone (Fig 1). Next, we examined the
effect of rotenone treatment on the histology of the adre-
nal gland. The adrenal cortex of control animals showed
the expected well-demarcated division among z. glomeru-
losa, z. fasciulata, and z. reticularis. While cells of z.
glomerulosa were arranged in the normal, irregular ovoid
clumps, separated by a delicate trabecular system and a
fine distribution of capillaries, those of z. fasciculata con-
sisted of narrow cords of secretory cells with a large mildly
stained cytoplasm, presenting a foamy appearance (Fig 2).
Also, cells of z. reticularis were smaller and more inten-
sively stained than those of z. fasciculate, and were ar-
ranged in an irregular network of glandular cells separated
by numerous wide diameter capillaries (Fig 2). Rotenone
treatment diminished the adrenal cortical width. Cells in
z. fasciculata and z. reticularis were compact, with an area
difficult to assign to either zone (Fig 2). Furthermore, nu-
clei, particularly in z. fasciculata, were rather small, inten-
sively stained, with quite a few pyknotic nuclei present
(Fig 2). The effects of rotenone were similar to those ob-
served in adrenals of animals treated with corticosterone
(not shown). Conversely, however, RU 486 treatment re-
sulted in a rather wide adrenal cortex, with a well-demar-
cated z. glomerulosa, but unclear demarcation between z.
reticularis and z. fasciculate. Both of these two areas were
very compact and exhibited intensively stained cells (Fig
2). The nuclei in z. reticularis and z. fasciculata in RU 486-
treated mice were small and hyperchromatic, with mini-
mal evidence of pyknotic nuclei (Fig. 2) Simultaneous ad-
ministration of the glucocorticoid antagonist RU 486 with
rotenone partially abrogated the effect of the later on the
adrenal gland (Fig 2). Treatment with rotenone and RU
486 resulted in an increased cortical width, with the resto-
ration of a very well demarcated z. glomerulosa. However,
the effect of RU 486 was more evident on cells of z. fascic-
ulata and z. reticularis which remained very compact with
intensively stained eosinophilic cytoplasm (Fig 2). These
two areas were also less defined and contained many py-
knotic nuclei, compared with adrenals from control ani-
mals (Fig 2).
Figure 1
Thymus/Body Weight Ratios in Rotenone-Treated 
Mice. Animals were treated and thymus were surgically 
removed, blotted and weighed. Data are means ± SEM from 
3–5 animals per group. *p < 0.05 compared to control.
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Opposite Modulation of Hepatic Apoptosis by Rotenone 
and RU 486
Rotenone has been demonstrated to increase hepatic ap-
optosis [1,7]. To evaluate whether this effect was mediated
via glucocorticoid-responsive pathways, we compared the
effect of rotenone with that of the glucocorticoid antago-
nist, RU 486. In livers of control mice, only about 3–4%
of hepatocytes are undergoing self-imposed destruction
(Fig 3). As expected, rotenone accelerated this process re-
sulting in a two-fold increase in the number of hepato-
cytes undergoing apoptosis (Fig 3). Conversely, treatment
with the glucocorticoid antagonist RU 486 resulted in
more than a 60% decrease in this process (Fig 3).
Figure 2
Effect of Rotenone on Adrenal Histology. Shown are representative sections of adrenal glands from control, rotenone-
treated, and RU 486-treated mice. Also shown is a representative section of adrenal gland from animals treated with the com-
bination of rotenone and RU 486. Tissues were handled and examined as described under "Materials and Methods". Micro-
graphs were taken at 200× magnification.
Control      RU 486 
Rotenone   Rotenone + RU 486 Journal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/2
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Effect of Rotenone on Glucocorticoid-inducible Gene 
Transcription
To probe whether the in vivo glucocorticoid-like action of
rotenone is mediated at the transcription level, mouse
mammary adenocarcinoma cells (1470.2) were transfect-
ed with pLTRLuc and treated with dexamethasone and/or
rotenone. Treatment of cells with 10 nM dexamethasone
for 6 hours, activated the reporter gene transcription ap-
proximately 25-fold (Fig. 4). Moreover, 50 nM dexameth-
asone treatment for 6 h further activated the reporter gene
transcription to 100-fold suggesting that the effect of dex-
amethasone on transactivation is dose-dependent (data
not shown). While dexamethasone increased reporter
gene activity (Fig 4), rotenone alone neither changed the
reporter gene activity at concentrations as high as 100 nM,
nor did alter the dexamethasone-induced transactivation
when it was added simultaneously with dexamethasone
(Fig 4). These results suggest that rotenone does not acti-
vate transcription of glucocorticoid-inducible Mouse
Mammary Tumor Virus promoter.
Molecular Fitting Studies
RMS fit was performed between rotenone and two gluco-
corticoid receptor agonists (corticosterone and dehydro-
corticosterone; Fig 5) as well as between rotenone and two
glucocorticoid receptor antagonists (ZK 98.299 and RU
486; Fig 5). In comparing rotenone with all of these com-
pounds, RMS values ranging from 0.87 to 1.4 were ob-
tained, suggesting minimum degree of similarities
between rotenone and any of these compounds, if any
(Table 1).
Serum Corticosterone Levels
In mice receiving drug-free diet, serum corticosterone lev-
els were 168 ± 28 ng/ml (Fig 6). When animals were given
a diet containing 600 ppm rotenone for 7 days, serum
corticosterone levels climbed significantly to 490 ± 33 ng/
ml, a 3-fold increase in these levels (Fig 6).
Figure 3
Hepatocellular Apoptosis in Response to Rotenone 
and RU486. Mice were treated and the frequency of apop-
totic hepatocytes were quantified as described under "Mate-
rials and Methods". Data are means ± SEM from 4–6 animals 
per group. *p < 0.05 compared to control. **p < 0.05 com-
pared to rotenone.
Table 1: RMS Fit Values for Rotenone Against Modulators of the 
Glucocorticoid Receptor
Compound RMS Value
Corticosterone 1.38
Dehydrocorticosterone 0.87
RU 486 1.03
ZK 98.299 1.40
Data are obtained using Alchemy™ program, Tripose Inc., St. Louis 
MO, as described under "Materials and Methods".
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Figure 4
Activation of Glucocorticoid Receptors by Dexame-
thasone in the Presence and Absence of Rotenone. 
Cell line 1470.2 derived from C127 mouse mammary adeno-
carcinoma cells were transfected with the glucocorticoid 
receptor promotor. Subsequently, receptor activation assays 
were performed as described under "Materials and Meth-
ods". Data are means ± SEM from 3 experiments each run in 
duplicates.
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Figure 5
Chemical Structures of Rotenone, Glucocorticcoid Agonists and Antagonists.Journal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/2
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Discussion
Glucocorticoid-Like Effects of Rotenone
Increases in hepatic apoptosis were observed in the livers
of rotenone-treated mice [1,7]. Since apoptosis can act as
a safeguard mechanism that allows an organ to purge it-
self of already transformed cells [1], increased apoptosis
may be a crucial event in explaining the anticarcinogenic
effect of rotenone [1,7]. However, how rotenone modu-
lates hepatocellular apoptosis remains unclear. In search
of an answer to this question, it is noteworthy that like ro-
tenone, glucocorticoids have hepatic anticarcinogenic ef-
fects [8]. These hormones modulate the expression of
oncogenes and apoptosis in a fashion similar to that ob-
served in animals treated with rotenone [1,9–11]. In
agreement with our previous studies [1,12], we observed
that while rotenone enhanced hepatic apoptosis, the glu-
cocorticoid antagonist RU 486 diminished this activity
(Fig 3). In order to further characterize the relationship
between rotenone and glucocorticoids, we compared their
effects on the thymus and adrenal glands; organs which
are also sensitive to glucocorticoids [13,14]. In this study,
exposure of mice to exogenous corticosterone significant-
ly reduced thymus/body weight ratios; this effect was
mimicked by rotenone (Fig 1). Furthermore, in rotenone-
treated mice the decrease in the ratio of adrenal-to-body
weight was completely eliminated by the simultaneous
administration of the glucocorticoid antagonist RU 486
with rotenone (not shown). Histological changes in adre-
nal glands in response to rotenone and RU 486 co-treat-
ment (Fig 2) resembled those known to occur in response
to exogenous corticosterone [14]. Based on these findings,
we initially hypothesized that rotenone may act as a glu-
cocorticoid agonist.
Mechanism of Rotenone-Induced Glucocorticoid Effects
Glucocorticoid agonists as well as antagonists were sub-
jected to molecular fitting analysis against rotenone. The
high RMS values indicate that it is highly unlikely that ro-
tenone interacts with the glucocorticoid receptor (Table
1). This conclusion was confirmed directly by the inability
of rotenone to modulate the glucocorticoid receptor-in-
ducible gene transcription (Fig 4). As it was highly unlike-
ly that rotenone directly modulated the glucocorticoid
receptor, our attention was drawn to the possibility that
the effect of rotenone may be mediated by corticosterone,
the endogenous ligand of this receptor. Consequently, we
investigated the influence of this compound on the home-
ostasis of corticosterone, the major glucocorticoid in
rodents. Surprisingly, a 3-fold increase in serum levels of
corticosterone was observed in rotenone-treated mice (Fig
6). Based on the well-known inhibitory effects of gluco-
corticoids on cell growth and DNA synthesis [8], our data
suggest that enhancing corticosterone secretion by roten-
one is likely to, at least in part, mediate the anti-hepato-
carcinogenic effect known to occur in response to this
compound [3].
Hormonal Disruption as Basis for Rotenone-Induced Anti-
hepatocarcinogenic Effect
In spite of advances made in the field of cancer research,
events leading to cancer and mechanisms of action by an-
ticancer agents remain elusive [15]. We [1,3] as well others
[7] have reported that the antihepatocarcinogenic activity
of rotenone may be produced by diminishing liver cell
proliferation and/or by enhancing hepatocellular apopto-
sis. We have also shown that rotenone alters hepatocellu-
lar transduction pathways in a manner consistent with a
pro-apoptotic effect [1]. Nonetheless, molecular
mechanisms involved remained unclear. In this study, we
present evidence showing that the antihepatocarcinogenic
effect of rotenone may be mediated, at least in part,
through elevated serum glucocorticoid levels, resulting
from exposure to this compound. Despite the fact that en-
docrine disruptors have been linked to numerous patho-
logical conditions [16], discovery of such compounds
may in contrast, lead to development of novel cancer pre-
ventive agents.
Conclusion
The data demonstrate that despite the fact that rotenone
produces histological and biochemical effects similar to
those produced by corticosterone, rotenone does not di-
rectly activate the glucocorticoid receptor. Glucocorticoid-
like-effects of rotenone may be a consequence of increas-
ing serum corticosterone levels caused as a result of
exposure to rotenone. This novel finding leads to the con-
clusion that rotenone is a unique endocrine disruptor of
glucocorticoids, and warrants further investigation of its
effects on homeostasis of other hormones. Although
Figure 6
Rotenone-Induced Increases in Serum Corticoster-
one Levels. Mice were treated and serum corticosterone 
levels were determined in livers as described under "Materi-
als and Methods". Data are means ± SEM from 3–5 animals 
per group. *p < 0.05 compared to control.
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mechanisms by which rotenone elevates serum corticos-
terone levels remain unclear, the possibility that rotenone
acts via a receptor-mediated mechanism to stimulate the
adrenal gland deserves further evaluation. Furthermore,
compounds structurally related to rotenone should be
screened to evaluate their potential as disruptors of gluco-
corticoid homeostasis.
Author's Contributions
JY performed the apoptosis assay. CE and BW carried out
the glucocorticoid receptor transfection and transactiva-
tion assay. RN and DY performed the molecular fitting
studies. AM performed the tissue histological evaluations.
MC analyzed serum corticosterone levels. MB conceived,
designed and coordinated the study. All authors partici-
pated in writing the manuscript.
Acknowledgements
This work is supported, in part, by NIH AG 18479 to MB. The authors are 
grateful to Ms Hongmei Meng for technical assistance.
References
1. Wang C, Youssef J, Saran B, Rothberg P, Cunningham ML, Molteni A
and Badr M Diminished energy metabolism and enhanced ap-
optosis in livers of B6C3F1 mice treated with the antihepa-
tocarcinogen rotenone. Mol Cell Biochem 1999, 201:25-32
2. Oberg K Site of action of rotenone in the respiratory chain.
Exp Cell Res 1961, 24:163-164
3. Cunningham ML, Soliman MS, Badr M and Matthews HB Rotenone,
an anticarcinogen, inhibits cellular proliferation but not per-
oxisome proliferation in mouse liver. Cancer Lett 1995, 95:93-97
4. King KL and Cidlowski JA Cell cycle regulation and apoptosis.
Annu Rev Physiol 1998, 60:601-617
5. Telford WG, King LE and Fraker PJ Evaluation of glucocorticoid-
induced DNA fragmentation in mouse thymocytes by flow
cytometry. Cell Prolif 1991, 24:447-459
6. Fryer C, Kinyamu HK, Rogatsky I, Garabedian MJ and Archer TK Se-
lective activation of the glucocorticoid receptor by steroid
antagonists in human breast cancer and osteosarcoma cells.
J Biol Chem 2000, 275:17771-17777
7. Isenberg J, Kolaja K, Ayoubi S, Watkins JB and Klaunig JE Inhibition
of Wy-14,643 induced hepatic lesion growth by rotenone.
Carcinogenesis 1997, 18:1511-1519
8. Henderson IC, Fischel RE and Loeb JN Suppression of DNA syn-
thesis by cortisone. Endocrinol 1971, 88:1471-1474
9. Henderson IC and Loeb JN Hormone-induced changes in liver
DNA synthesis: effects of glucocorticoids and growth hor-
mones: growth and DNA polymerase activity. Endocrinol 1974,
93:1637-1643
10. Denis G, Humbelt M, Varlaet J, Boniver J and Defresne MP p53, Bax
and Bcl-2 in vivo expression in the murine thymus after ap-
optogenic treatments. Anticancer Res 1998, 18:3315-3321
11. Medh RD, Saeed MF, Johnson BH and Thompson EB Resistance of
human leukemic CEM-C1 cells is overcome by synergism be-
tween glucocorticoid and protein kinase A pathways: corre-
lation with c-myc suppression. Cancer Res 1998, 58:3684-3693
12. Youssef J and Badr M Hepatocarcinogenic potential of the glu-
cocorticoid antagonist RU 486 in B6C3F1 mice: effect on
apoptosis, expression of oncogene and the tumor suppressor
gene p53. Mol Can 2003, 2:3
13. Selye E and Hall C Pathological changes induced in various spe-
cies by overdosage with desoxycorticosterone.  Arch Pathol
1943, 36:19-28
14. Skelton FR Production and inhibition of hypertensive disease
in rat by corticosterone. Endocrinol 1958, 62:364-369
15. Gopala K, Shiff S, Telang N, Das K, Kohgo Y, Narayan S and Li H Car-
cinogenesis: The more we seek to know the more we need
to know-challenges in the post genomic era. J Carcinogenesis
2003, 2:1
16. Birnbaum L and Cummings A Dioxins and Endometriosis: A
Plausible hypothesis. Environ Health Perspect 2002, 110:15-21